From: Tumor immunogenomic signatures improve a prognostic model of melanoma survival
Variable | Discovery (N = 139) | Validation 1 (N = 70) | Pooled (Discovery + validation 1) (N = 209) | ||||||
---|---|---|---|---|---|---|---|---|---|
ß | HR (95% CI) | P | ß | HR (95% CI) | P | ß | HR (95% CI) | P | |
TMB (low) | 1.26 | 3.52 (2.00–6.20) | 1.30E–05 | 1.05 | 2.86 (1.23–6.62) | 0.01 | 1.21 | 3.36 (2.10–5.36) | 4.01E–07 |
IFNγRes | 0.46 | 0.63 (0.48–0.84) | 1.43E–03 | – 0.76 | 0.47 (0.27–0.82) | 8.00E–03 | − 0.50 | 0.60 (0.48–0.77) | 4.99E–05 |
MacReg | 0.48 | 0.62 (0.43–0.88) | 8.18E–03 | – 0.59 | 0.56 (0.35–0.89) | 0.02 | − 0.50 | 0.61 (0.46–0.80) | 3.87E–04 |
Tumor infiltration (regional) fraction | 0.05 | 0.95 (0.91–0.99) | 0.02 | – 0.04 | 0.96 (0.90–1.02) | 0.19 | − 0.05 | 0.96 (0.92–0.99) | 8.00E–03 |
Lymphocyte infiltration signature score | 0.22 | 0.80 (0.67–0.97) | 2.29E–02 | – 0.25 | 0.78 (0.62–0.99) | 0.04 | − 0.22 | 0.80 (0.70–0.93) | 2.40E–03 |
Number of CNV segments | 0.00 | 1.00 (1.00–1.00) | 0.02 | 3.00E–03 | 1.00 (1.00–1.01) | 0.07 | 1.74E–03 | 1.00 (1.00–1.00) | 4.00E–03 |
Activated mast cells | 0.22 | 1.24 (1.01–1.53) | 0.04 | 17.38 | 3.55E + 7 (7.40E − 07–1.70E + 21) | 0.28 | 11.57 | 1.06E + 5 (7.54–1.49E + 09) | 0.02 |